

## Press Release

### Jambuwala Pharmaceuticals Limited

November 29, 2018



#### Rating Assigned

<b>Total Bank Facilities Rated*</b>	Rs. 10.00 Cr.
<b>Long Term Rating</b>	ACUITE B / Outlook: Stable

\* Refer Annexure for details

#### Rating Rationale

Acuité has assigned long-term rating of '**ACUITE B**' (read as **ACUITE B**) to the Rs. 10.00 crore bank facilities of Jambuwala Pharmaceuticals Limited (JPL). The outlook is '**Stable**'.

JPL, based at Ahmedabad (Gujarat), was incorporated in 2017. The company is engaged in manufacturing, trading of generic and general medicines in pharmaceutical industry made for human consumption. The manufacturing facility is located at Sanand (Ahmedabad) with installed capacity of 6000 lakhs units of Tablets and 600 lakhs of Capsules per annum.

#### Analytical Approach

Acuité has considered the standalone business and financial risk profiles of the JPL to arrive at this rating.

### Key Rating Drivers

#### Strengths

- **Experienced management**

The key promoters, Mr. Pranlal Bhailal Shah and Mr. Hiren Vijaykumar Doshi possess more than three decades of experience in the commodities, broking and pharmaceutical industry. Other promoters, Mr. Kamal Shah and Mr. Chintan Pranlal Shah possess a decade of experience in the commodity trading and brokerage business through their association with other companies in Jambuwala Group. The rich experience and expertise of promoters in the same line of business will ensure timely execution of project.

#### Weaknesses

- **Project off take risk**

The project is yet to start. The commercial operations are expected to commence from April 2019, thus, the project faces off-take risk. The project has total cost of Rs.14.91 crore which will be funded by Rs.6.00 crore of term loan, Rs.2.00 crore of working capital loan and rest from promoters' contribution in the form of equity and unsecured loan. However, the same is mitigated to some extent as the project is 65.00 percent completed and extensive promoters' experience will help timely execution.

- **Intense competition and regulatory risk**

The company operates in pharmaceutical, generic and general medicine sector, which is marked by the presence of large number of players which will put pressure on margins and restricts bargaining power with the clients. Further, the industry is highly regulated by the regulatory board and requires many licenses. Any change in regulation or government policy will have adverse impact on business of the company.

#### Outlook: Stable

Acuité believes that JPL will maintain a 'Stable' outlook and benefit from the experience of its management. The outlook may be revised to 'Positive' if the company achieves its projected scale of operations and profitability. Conversely, the outlook may be revised to 'Negative' in case of delays in project implementation.

### About the Rated Entity - Key Financials

	Unit	FY18 (Actual)
Operating Income	Rs. Cr.	0.00
EBITDA	Rs. Cr.	-0.02
PAT	Rs. Cr.	-0.02
EBITDA Margin	(%)	0.00
PAT Margin	(%)	0.00
ROCE	(%)	-1.95
Total Debt/Tangible Net Worth	Times	0.23
PBDIT/Interest	Times	0.00
Total Debt/PBDIT	Times	-18.89
Gross Current Assets (Days)	Days	0

### Status of non-cooperation with previous CRA (if applicable)

Not Applicable

### Any other information

None

### Applicable Criteria

- Default Recognition - <https://www.acuite.in/criteria-default.htm>
- Trading Entities - <https://www.acuite.in/view-rating-criteria-6.htm>
- Manufacturing Entities - <https://www.acuite.in/view-rating-criteria-4.htm>
- Financial Ratios And Adjustments - <https://www.acuite.in/view-rating-criteria-20.htm>

### Note on complexity levels of the rated instrument

<https://www.acuite.in/criteria-complexity-levels.htm>

### Rating History (Upto last three years)

Not Applicable

### \*Annexure – Details of instruments rated

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Cr.)	Ratings/Outlook
Proposed Cash Credit	Not Applicable	Not Applicable	Not Applicable	2.00	ACUITE B / Stable
Proposed Term Loan	Not Applicable	Not Applicable	Not Applicable	6.00	ACUITE B / Stable
Proposed Long Term Bank Facility	Not Applicable	Not Applicable	Not Applicable	2.00	ACUITE B / Stable

### Contacts

Analytical	Rating Desk
Avadhoot Mane Senior Analyst - Rating Operations Tel: 022 49294022 <a href="mailto:avadhoot.mane@acuiteratings.in">avadhoot.mane@acuiteratings.in</a>	Varsha Bist Manager - Rating Desk Tel: 022-67141160 <a href="mailto:rating.desk@acuite.in">rating.desk@acuite.in</a>
Rupesh Patel Analyst - Rating Operations Tel: 02249294032 <a href="mailto:rupesh.patel@acuiteratings.in">rupesh.patel@acuiteratings.in</a>	

**About Acuité Ratings & Research:**

Acuité Ratings & Research Limited (Erstwhile SMERA Ratings Limited) is a full-service Credit Rating Agency registered with the Securities and Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI), for Bank Loan Ratings under BASEL-II norms in the year 2012. Since then, it has assigned more than 6,000 credit ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Mumbai.

**Disclaimer:** An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuité ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuité ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuité.